Patents by Inventor Keith M DeVries

Keith M DeVries has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6624313
    Abstract: A process of preparing compounds having the formula I: or an optical isomer or racemic or optically active mixture thereof, which are useful as selective kappa-receptor agonists.
    Type: Grant
    Filed: April 26, 2002
    Date of Patent: September 23, 2003
    Assignee: Warner-Lambert Company LLC
    Inventors: Keith M. DeVries, Michel A. Couturier, Brian M. Andresen, John L. Tucker, Fumitaka Ito
  • Publication number: 20030158428
    Abstract: The invention relates to processes for preparing a compound of the formula 1
    Type: Application
    Filed: January 30, 2002
    Publication date: August 21, 2003
    Applicant: Pfizer Inc.
    Inventors: Keith M. Devries, Stephane Caron, Philip D. Hammen, Geraldine P. Taber, John L. Tucker, Peter R. Rose, Ronald J. Post, Brian K. Raymer
  • Publication number: 20020161241
    Abstract: A process of preparing compounds having the formula I: 1
    Type: Application
    Filed: April 26, 2002
    Publication date: October 31, 2002
    Applicant: Pfizer Inc.
    Inventors: Keith M. DeVries, Michel A. Couturier, Brian M. Andresen, John L. Tucker, Fumitaka Ito
  • Patent number: 6410750
    Abstract: The present invention provides novel processes for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid. Also provided are novel intermediates used in those processes. Further, the 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid prepared by the novel processes can be further reacted to yield known indole 2-carboxamides and derivatives thereof possessing glycogen phosphorylase inhibitory activity, which are useful in the treatment of mammals, especially human beings, having glycogen phosphorylase dependent diseases or conditions.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: June 25, 2002
    Assignee: Pfizer Inc.
    Inventors: Keith M. DeVries, Darrell E. Fox, Philip D. Hammen, Dennis J. Hoover, Jeffrey B. Jorgensen
  • Patent number: 6359137
    Abstract: Trovafloxacin acid salts are prepared via the hydrolysis of imine intermediates using mineral acid including, but not limited to, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, nitric acid, sulfuric acid, phosphoric acid, hydrochloric acid, hydrobromic acid, tartaric acid, citric acid, acetic acid, and maleic acid. Trovafloxacin acid salts are useful as antibiotic agents.
    Type: Grant
    Filed: August 26, 1999
    Date of Patent: March 19, 2002
    Assignee: Pfizer Inc.
    Inventors: Timothy Norris, Keith M. DeVries, Peter R. Rose
  • Patent number: 6291489
    Abstract: This invention relates to processes for preparing compounds of the formula (I) and to processes for preparing certain intermediates of the formula wherein R1 is nitro, amino or protected amino; R2 is H, fluoro, chloro CF3, nitro, (C1-C4)alkyl, (C1-C4)alkoxy, amino or protected amino; and X1 is OH or a suitable leaving group, used in that process. The invention also relates novel to compounds of the formulae (II).
    Type: Grant
    Filed: May 5, 1999
    Date of Patent: September 18, 2001
    Assignee: Pfizer Inc.
    Inventors: Keith M DeVries, Robert L. Dow, Stephen W. Wright
  • Patent number: 6124457
    Abstract: The instant invention relates to intermediates of Formula II, ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification, and to processes for preparing such intermediates. This invention also relates to processes for preparing compounds of Formula III, ##STR2## and enantiomers thereof, wherein R.sup.2, R.sup.3 and R.sup.4 are as defined in the specification. Compounds of Formula II and Formula III are intermediates in the preparation of a potent .beta..sub.3 adrenergic receptor agonist. The instant invention also relates to processes for preparing the .beta..sub.3 adrenergic receptor agonist using the compounds of Formula II and Formula III.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: September 26, 2000
    Assignee: Pfizer Inc.
    Inventors: Keith M. DeVries, Jeffrey W. Raggon, Ravi M. Shanker, Frank J. Urban, Brian C. Vanderplas
  • Patent number: 6096893
    Abstract: A new pyridine carbaldehyde is useful for the synthesis of compounds which are effective for treating neurodegeneration conditions and CNS trauma.
    Type: Grant
    Filed: August 16, 1999
    Date of Patent: August 1, 2000
    Assignee: Pfizer Inc.
    Inventor: Keith M. DeVries
  • Patent number: 6090942
    Abstract: The instant invention relates to intermediates of Formula II, ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification, and to processes for preparing such intermediates. This invention also relates to processes for preparing compounds of Formula III, ##STR2## and enantiomers thereof, wherein R.sup.2, R.sup.3 and R.sup.4 are as defined in the specification. Compounds of Formula II and Formula III are intermediates in the preparation of a potent .beta..sub.3 adrenergic receptor agonist. The instant invention also relates to processes for preparing the .beta..sub.3 adrenergic receptor agonist using the compounds of Formula II and Formula III.
    Type: Grant
    Filed: September 29, 1999
    Date of Patent: July 18, 2000
    Assignee: Pfizer Inc.
    Inventors: Keith M. DeVries, Jeffrey W. Raggon, Ravi M. Shanker, Frank J. Urban, Brian C. Vanderplas
  • Patent number: 6031114
    Abstract: A method for preparing hydroxamic acid derivatives which are useful as analgesic, antiinflammatory, or neuroprotective agents.
    Type: Grant
    Filed: August 16, 1999
    Date of Patent: February 29, 2000
    Assignee: Pfizer Inc.
    Inventors: Keith M. DeVries, Brian C. Vanderplas
  • Patent number: 6013808
    Abstract: A process of purifying a (6-chloro-2-carbazolyl)methyl-malonic acid di(C.sub.1 -C.sub.6 alkyl) ester of Formula (I): ##STR1## wherein R.sub.a and R.sub.b must be the same and are selected from the group consisting of C.sub.1 -C.sub.6 alkyl; comprises phase separating one or more impurities from said carbazole ester at least once wherein the solvent used to carry out said phase separation is acetic acid. In a preferred embodiment said acetic acid is glacial acetic acid which is maintained at a temperature of from about 30.degree. to about 110.degree.0 C. and said carbazole ester is obtained in a purity of at least 99.90% by weight, so that the amount of impurities present therein is 0.10% or less by weight. In a more preferred embodiment of said process, said temperature is from about 50.degree. to about 70.degree. C., and said phase separation is carried out only once.
    Type: Grant
    Filed: April 15, 1999
    Date of Patent: January 11, 2000
    Assignee: Pfizer Inc.
    Inventors: Philip D. Hammen, Peter R. Rose, John L. Tucker, Keith M. Devries, Diane M. Rescek
  • Patent number: 5916902
    Abstract: This invention relates to a process for preparing the compound having the formula ##STR1## which comprises i) heating the compound of formula ##STR2## wherein R.sup.3 is R.sup.4 or benzyl and R.sup.4 is R.sup.5 C(.dbd.O), R.sup.5 C(.dbd.O) or R.sup.5 SO.sub.2 wherein R.sup.5 is (C.sub.1 -C.sub.6)alkyl or (C.sub.6 -C.sub.10)aryl(C.sub.1 -C.sub.6)alkyl;at an elevated temperature in the presence of a base with the proviso that when R.sup.3 in the resultant product is R.sup.4 said product is ii) further treated with an aqueous mineral acid at an elevated temperature followed by iii) treatment of the product of ii) with a) a benzylating agent in the presence of a base or b) benzaldohyde in the presence of a reducing agent and an acid.
    Type: Grant
    Filed: April 16, 1997
    Date of Patent: June 29, 1999
    Assignee: Pfizer Inc.
    Inventors: Keith M. Devries, Anabella Villalobos